This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

(Currently Amended): A compound of formula I

$$R^1 - \underbrace{\stackrel{E}{\underset{W}{\longleftarrow}} R^2}_{R^2} X - Y - T$$

in which

R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA or NHSO₂A,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R¹ and R² together are alternatively a bicyclically or spirocyclically bonded 3 to

7 membered carbocyclic or heterocyclic ring having from 0 to 3 N, O and/or S

atoms,

$$\begin{split} R^3 & \quad \text{is H or Λ, is H, Λ, H $C=C$: CH_2, CH_3 $C=C$: CH_2, CH_2 $$$

R4 is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or

- azetidine-1,2-diyl,
- W is N. CR³ or an sp² hybridised carbon atom.
- E together with W is a 3 to 7-membered saturated carboeyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atom which optionally contains a double bond;
- D is phenyl, pyridyl or thienyl, which in each case is monosubstituted or disubstituted by Hal, a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR² or CON(R²)₂
- G is $(\underline{CH_2})_n \underline{or} (\underline{CH_2})_n \underline{NH_-}$, $-[\underline{C(R^4)_2}]_n [\underline{C(R^4)_2}]_n NR^2$, $-[\underline{C(R^4)_2}]_n \underline{O}$, $-[\underline{C(R^4)_2}]_n \underline{S}$ $\underline{or} -[\underline{C(R^4)_n} -\underline{C(R^4)}]_n - \underline{C(R^4)_n}$
- X is $\underline{\text{CONH}}_{\cdot}$ $[\underline{\text{C(R^4)}_2}]_n \underline{\text{CONR^3}}^{3}[\underline{\text{C(R^4)}_2}]_n ... \underline{\text{(C(R^4)}_2}]_n \underline{\text{NR^3}}^{3}\underline{\text{CO[C(R^4)}_2}]_n ... \\ -[\underline{\text{C(R^4)}_2}]_n \underline{\text{NR^3}}^{3}[\underline{\text{C(R^4)}_2}]_n ... \underline{\text{(C(R^4)}_2}]_n \underline{\text{CO[C(R^4)}_2}]_n ... \underline{\text{(C(R^4))}_2}]_n ... \underline{\text{(C(R^4))}_2}]_n \underline{\text{CO(C(R^4))}_2}... \\$
- Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F, alkylene, eyeloalkylene, Het-diyl or Ar diyl,
- T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen, a monocyclic or bicyclic, saturated or unsaturated carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is monosubstituted or disubstituted by = O, = S, = NR², = N CN, = N NO_{2x} = NOR², = NCOOR³ or = NOCOOR³ and which is optionally further monosubstituted, disubstituted or trisubstituted by R², Hal, A, [C(R⁴)₂]_n Ar, [C(R⁴)₂]_n Het, [C(R⁴)₂]_n veltoalkyl, OR², N(R²)_{2x} NO_{2x} CN, COOR², CON(R³)_{2x} NR²COA, NR²COA, NR²COA, NR²COA, COR², SO₂NR² and/or S(O)₂A;
- A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H
 atoms are each optionally replaced by F, unbranched or branched alkyl having
 1-10 carbon atoms in which one or two CH₂ groups are each optionally
 replaced by O or S atoms and/or by CH=CH groups and/or in addition 1-7 H

- atoms are each optionally replaced by F.
- Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂; CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³; SO₂N(R³)₂, S(O)₂A, (COR³)₂, COOR³;
- Ar'—is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR⁴, N(R⁴)₂₇, NO₂₇

 CN, COOR⁴, CON(R⁴)₂₅, NR⁴COA, NR⁴CON(R⁴)₂₅, NR⁴SO₂A, COR⁴;

 SO₂N(R⁴)₂₇, S(O)₂A,—IC(R⁴)₁)₂₇, COOR⁴ or—OIC(R⁴)₁)₂₇, COOR⁴;
- Het is a monocyclic-or-bicyclic, saturated, unsaturated or aromatic-heterocyclic ring-having-from I-to 4-N, O and/or-S atoms which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, [C(R⁴)₂]_n-Ar₁, [C(R⁴)₂]_n-Het', [C(R⁴)₂]_n-eyeloalkyl, OR²₇-N(R²)₂, NR²CON(R²)₂, NO₂-CN₁, [C(R⁴)₂]_n-COOR², [C(R⁴)_n-COOR², [C(R⁴)_n-COOR²]_n-COOR², [C(R⁴)_n-COOR²]_n-COOR², [C(R⁴)_n-COOR²]_n-COOR², [C(R⁴)_n-CO
- Het is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, =S, =N(R⁴)_{2r}, Hal, A, OR⁴, N(R⁴)_{2r}, NO_{2r}, CO, COOR⁴, COOR⁴, CON(R⁴)_{2r}, NR⁴COA, N
- Hal is F, Cl, Br or I, and
- n is 0. 1 or 2-and
- o is 1, 2 or 3;

or a and pharmaceutically usable <u>prodrug</u> derivative, solvate, salt, or stereoisomer thereof, including mixtures thereof in all ratios.

wherein said pharmaceutically usable prodrug derivative is a compound of formula I which has been modified with an alkyl group, acyl groups, sugar, oligopeptide, or biodegradable polymer and which is cleavable to form a compound of formula I.

(Cancelled):

3.	(Cancelled):
4.	(Cancelled):
5.	(Cancelled):
5.	(Cancelled):
7.	(Cancelled):
3.	(Cancelled):
9.	(Cancelled):
10.	(Cancelled):
11.	(Cancelled):
12.	(Cancelled):
13.	(Cancelled):
14.	(Cancelled):
15.	(Cancelled):
16.	(Cancelled):
17.	(Cancelled):

18.

(Cancelled):

- 19. (Cancelled):
- 20. (Cancelled):
- 21. (Cancelled):
- 22. (Cancelled):
- (Currently Amended): A compound according to Claim 1, wherein said compound is selected from:
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide.$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-[[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]]-(R)-pyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-piperidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-[[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]]-(R)-pyrrolidine-1-2-dicarboxamide,
- 1-N [(4-chlorophenyl)]-2-N [[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]] (R) pyrrolidine-1-2-dicarboxamide.
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,$
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide.

- N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,
- 3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide.
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3.4-dicarboxamide,
- 3-N-[(4-chlorophenyl)]-4-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,
- $3-N-[(4-chlorophenyl)-4-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3.4-dicarboxamide.$
- 3-N-[(4-chlorophenyl)] 4-N-[[4-(2-oxo-2H-pyridin-1-yl)phenyl]] (R)-oxazolidine-3,4-dicarboxamide.
- 3-N [(4-chlorophenyl)] 4-N [[4-(2-oxo-2H-pyridin 1-yl)phenyl]] (4R,5S) 5-methyloxazolidine 3,4-dicarboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3.4-dicarboxamide.$
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3\cdot N\cdot [(4\cdot chlorophenyl)]\cdot 4\cdot N\cdot \{[4\cdot (2\cdot oxo\cdot 2H\cdot pyrazin\cdot 1\cdot yl)phenyl]\}\cdot (4R,5S)\cdot 5\cdot methyloxazolidine 3,4\cdot dicarboxamide,$
- 3 N [(4 chlorophenyl)] 4 N [[4 (2 oxo-2H pyrazin-1 yl)phenyl]] (R) oxazolidine-3,4-dicarboxamide;
- 3-N [(4-chlorophenyl)]-4-N-[[3-chloro-4-(2-oxo-2H-pyridin-1-yl)phenyl]] (R)-oxazolidine 3.4-dicarboxamide.
- 3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide.
- 3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo-1λ⁶-thiazolidine-3,4-dicarboxamide,

- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1dioxo-1λ⁶-thiazolidine-3.4-dicarboxamide.
- 3-N-[(4-chlorophenyl)]-4-N-[[4-(2-oxo-2H-pyridin-1-yl)phenyl]]-(R)-thiazolidine-3-4-dicarboxamide.
- N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl) oxazolidine-5-carboxamide.
- N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide.
- N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-earboxamide.
- 1 N [(5 chloropyridin 2 yl)] 2 N [[4 (2 oxo 2H pyridin 1 yl)phenyl]] (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide.
- $1-N-[(5-\text{chloropyridin-}2-yl)]-2-N-\{[4-(3-\text{oxomorpholin-}4-yl)\text{phenyl}]\}-(2R,4R)-4-\text{hydroxypyrrolidine-}1.2-\text{dicarboxamide}.$
- 1 N [(5-ehloropyridin 2 yl)] 2 N [[4 (2 oxo 2H pyrazin 1 yl)phenyl]] (2R,4R) 4hydroxypyrrolidine 1,2-dicarboxamide,
- 1 N-[(5-ehloropyridin 2-yl)] 2 N-[[3-fluoro 4 (2-oxo-2H-pyridin-1-yl)phenyl]]-(2R,4R) 4-hydroxypyrrolidine 1,2-dicarboxamide,
- $1.N = \{(5-\text{chloropyridin} \ 2.yl)\} \ 2.N = \{(4-(2-\text{oxo} \ 2H-\text{pyridin} \ 1.yl) \text{phenyl}\}\} \ (R) \ 4,4-dimethoxypyrrolidine} \ 1,2 \ diearboxamide,$
- 1-N [(4 chlorophenyl)]-2-N-[[4 (2-oxo-2H-pyridin-1-yl)phenyl]]-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide;
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4hvdroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

- 1 N [(4 chlorophenyl)] 2 N [[4 (2 oxo 2*H* pyridin 1 yl)phenyl]] (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-[[4-(2-oxopyrazin-1-yl)phenyl]]-(2R,4R)-4-hvdroxypyrrolidine-1,2-dicarboxamide,
- 1 N [(4 chlorophenyl)] 2 N [[3 fluoro 4 (2 oxo 2H pyridin 1 yl)phenyl]] (2R,4R)-4 hydroxypyrrolidine 1,2 dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,3R)-3-hvdroxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-hvdroxypyrrolidine-1,2-dicarboxamide.
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4azidopyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4acetaminopyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,\\$

- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,\\$
- (3R, SR)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl) pyrrolidin-3-yl isobutyrate,
- (3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)phenylcarbamoyl]pyrrolidin-3-yl propionate,
- $\label{eq:continuous} (3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl] pyrrolidin-3-yl acetate,$
- $\label{lem:control} 4-N-[(4-chlorophenyl)]-5-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-4, 5-dicarboxamide,$
- $\label{lem:continuous} 4-N-[(4-chlorophenyl)]-5-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-4, 5-dicarboxamide,$
- $4 \ N \ [(4 \ \text{chlorophenyl})] \ 5 \ N \ \{[4 \ (2 \ \text{oxo} \ 2H \ \text{pyridin} \ 1 \ \text{yl}) \text{phenyl}]\} \ 1,3 \ \text{dioxolane} \ 4,5 \text{dicarboxamide};$
- 4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,
- 4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,
- 4 N [(4 chlorophenyl)] 5 N [[4 (2 oxo 1*H* pyridin 1 yl)phenyl]] 1,3 dioxolane 2,2-dimethyl 4.5 dicarboxamide,

- 1-N-[4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1-BOC-piperazine-1.2-dicarboxamide.
- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\} piperazine-1, 2-dicarboxamide. \\$
- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-oxazinane-3, 4-dicarboxamide$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-ethynyl-4hydroxypyrrolidine-1,2-dicarboxamide,
- 6-N-[(4-chlorophenyl)]-7-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-oxa-6-azaspiro[2.4]heptane-6.7-dicarboxamide.
- $1-N-[(6-chloropyridin-3-yl)]-2-N-[\{4-(2-oxo-2H-pyridin-1-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- $\frac{1\ N\ \{(6\ chloropyridin\ 3\ yl)\}\ 2\ N\ \{[4\ (2\ oxo\ 2H\ pyrazin\ 1\ yl)phenyl]\}\ (2R,4R)\ 4}{hydroxypyrrolidine\ 1,2\ dicarboxamide,}$

- $\label{lem:constraint} $$1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-4-oxopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[2-(4-chlorophenyl)acetyl]-4hydroxypyrrolidine-2-carboxamide,
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(4-chlorobenzoyl)-4hydroxypyrrolidine-2-carboxamide,

- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)] 2-N-[[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]] (2R,4R) 4-methoxypyrrolidine-1,2-dicarboxamide.
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$
- 1 N [(4 chlorophenyl)] 2 N [[4 (2 oxo 2H pyrazin 1 yl)phenyl]] (2R,4R) 4methoxypyrrolidine 1,2 dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-[\{4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,$
- N-[4 (3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1 (1-1H-indol-3-ylmethanoyl)-4hydroxypyrrolidine-2-carboxamide,
- N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 (1 1H indol 6 ylmethanoyl) 4hydroxypyrrolidine 2 earboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide.$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- $\frac{1-N\left[(4-\text{chlorophenyl})\right]\cdot 2-N\cdot\left[\left\{4\cdot(2-\text{oxo}\cdot 1H-\text{pyridin}\cdot 1\text{ yl})\text{phenyl}\right]\right]\cdot (2R,4S)\cdot 4-\text{ethynyl}\cdot 4-\text{hydroxypyrrolidine}\cdot 1,2-\text{dicarboxamide},$
- 1 N [(4 chlorophenyl)] 2 N [[4 (2 oxo 2H pyrazin 1 yl)phenyl]] (2R,4S) 4 ethynyl 4 hydroxypyrrolidine 1,2 dicarboxamide,
- 1-N [(4 chlorophenyl)] 2 N-[[4 (2 oxo-2H-pyridin-1-yl)phenyl]] 4,4 difluoro (R)pyrrolidine 1,2 dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-[[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]]-(2R,4R)-4-methoxypyrrolidine 1,2 dicarboxamide,
- 1 N [(4 chlorophenyl)] 2 N [[2 fluoro 4 (2 oxo 2H pyridin 1 yl)phenyl]] (R) pyrrolidine 1,2 dicarboxamide,

- 1 N [(4 chlorophenyl)] 2 N -[[2 fluoro 4 (2 oxo 2H pyridin 1 yl)phenyl]] (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide,
- $2-N-[(4-chlorophenyl)]-1-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide.$
- 2-N-[(4-chlorophenyl)]-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-pyrrolidine-1,2-dicarboxamide
- 1 N [(4 chlorophenyl)] 2 N [[4 (2 oxo 3 methoxy 2H pyridin 1 yl)phenyl]]-(2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide;
- 1 N [(4 chlorophenyl)] 2 N [[4 (2-oxo-3-methoxy-2H-pyridin-1-yl)phenyl]] (R)-pyrrolidine 1,2 dicarboxamide,
- $N-(4-chlorophenyl)-(R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}pyrrolidine-2-carboxamide,\\$
- $N-(4-chlorophenyl)-(S)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl] acetyl\} pyrrolidine-2-carboxamide.$
- $N-(4-chlorophenyl)-(2R,4R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,\\$
- $N-(4-chlorophenyl)-(2R,4S)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,$
- $N-(4-chlorophenyl)-(2S,4R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,$
- $\label{eq:N-(4-chlorophenyl)-(8)-1-(2-(4-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(2-chlorophenyl)-(8)-1-(8)$
- N (4-chlorophenyl) (S) 1 {2 [4 (2-oxopyrrolidin-1-yl)phenyl]acetyl}pyrrolidine 2-earboxamide:
- $N. (4 \ chlorophenyl) \ (R). \ 1. \ \{2. [4. (2 oxopyrrolidin-1-yl)phenyl] acetyl\} pyrrolidine. 2-earboxamide.$
- N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl] pyrrolidine-2-carboxamide.
- N (4 chlorophenyl) (R) 1 [4 (2 oxopiperidin 1 yl)phenyloxycarbonyl]pyrrolidine 2-carboxamide.

- 1 N [(4 chlorophenyl)] 2 N [[4 (2 oxo 2H pyrazin 1 yl)phenyl]] (2R,4R) 4-ethoxypyrrolidine 1,2 dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
- I-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,$
- 1 N [(4 chlorophenyl)] 2 N [[4 (2 oxo 1*H* pyrazin 1 yl)phenyl]] (R) 2,5-dihydropyrrole 1,2 dicarboxamide,
- 1-N [(4-chlorophenyl)] 2-N [[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]] (R) 2,5-dihydropyrrole-1,2-dicarboxamide,
- $1-N-[\{4-chlorophenyl\}]-2-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-\{R\}-2,5-dihydropyrrole-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,3S)-3-hvdroxypyrrolidine-1.2-dicarboxamide.
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4S)-4hvdroxypyrrolidine-1,2-dicarboxamide,
- 1 N [(4 chlorophenyl)] 2 N [[2 methoxycarbonyl 4 (3 oxomorpholin 4 yl)phenyl]](2R,4R) 3 hydroxypyrrolidine 1,2 dicarboxamide,

- 1-N-[(4-chlorophenyl)]-2-N-{[2-carboxy-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S,4R)-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,\\$
- $1-N-[(4-bromophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-[N-methoxycarbonylmethyl-N'-[4-(3-exomorpholin-4-yl)phenyl]]-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
- 1.N-[(4.chlorephenyh)]-2.N-[[4.(3-exemorpholin-4-yl)cyclohexan-1-yl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- $\frac{1 \cdot N \left[(4 \cdot chlorophenyl) \right] \cdot 2 \cdot N \left[\left[4 \cdot (2 \cdot iminopyrrolidin \cdot 1 \cdot yl)phenyl \right] \right] \cdot (2R,4R) \cdot 4}{hydroxypyrrolidine \cdot 1,2 \cdot dicarboxamide;}$
- 1-N-[(4-chlorophenyl)] 2-N-[[3-methyl-4-(2-iminopyrrolidin-1-yl)phenyl]] (2R,4R)-4-hydroxypyrrolidin-1,2-dicarboxamide:
- 1-N-[(4-chlorophenyl)]-2-N-[4-[2-[(E)-cyanimino]imidazolidin-1-yl)phenyl]}(2R.4R) 4 hydroxypyrrolidine 1,2 dicarboxamide:
- 1 N [(4 chlorophenyl)] 2 N [[4 (2 imino 5 methylthiazol 3 yl)phenyl]] (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide;

1-N-[(4-chlorophenyl)]-2-N-[[2-aminocarbonyl-4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide;

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-hydroxy-2-methylovrrolidine-1.2-dicarboxamide.

N-[4-(3-oxomorpholin-4-yl)phenyl] (2R,4R) 1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl] 4-hydroxypyrrolidine-2-carboxamide;

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 thiophen 3 ylacryloyl] 4hydroxypyrrolidine 2-carboxamide,

N [4 (3-oxomorpholin 4-yl)phenyl] (2R,4R) 1 [(2E,4E) 5-phenylpenta 2,4-dienyloyl] 4-hydroxypyrrolidine 2-carboxamide.

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-methylfuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-earboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 thiophen 2 ylacryloyl] 4-hydroxypyrrolidine 2 earboxamide,

N-[2-fluoro-4 (3-oxomorpholin-4-yl)phenyl]-(2R,4R) 1-[(E)-3 (5-chlorothiophen-2-yl)acryloyl] 4-methoxypyrrolidine-2-carboxamide,

N.[2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorothiophen 2-yl)acryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N-[4 (3-oxomorpholin-4-yl)phenyl] (2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide.

N [4 (3 exomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (4 chlorophenyl)acryloyl] 4-methoxypyrrolidine 2 carboxamide.

N-[4 (3-oxomorpholin-4-yl)phenyl] (2R,4R) 1-[(E) 3 (3,4-dichlorophenyl)acryloyl]4-methoxypyrrolidine 2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1H-imidazol-4-ylacryloyl]-4hydroxypyrrolidine-2-carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorothiophen 2yl)acryloyl] 4 methoxypyrrolidine 2 carboxamide, N [4 (3-oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5-chlorofuran 2 yl)acryloyl] 4hydroxynyrrolidine 2 carboxamide.

N-[4 (3-oxomorpholin 4-yl)phenyl] (2R,4R) 1 [(E) 3 (5-chlorofuran 2-yl)acryloyl] 4-methoxypyrrolidine 2-carboxamide.

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide.

N [4 (3 exemorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (3,4 dichlorophenyl)acryloyl] 4-ethoxypyrrolidine 2-earboxamide,

N-[4-(3-exomorpholin-4-yl)phenyl] (2R,4R) 1-[(E)-3-(5-chlorofuran-2-yl)acryloyl] 4-cthoxypyrolidine-2-carboxamide.

N-[4 (3-oxomorpholin-4 yl)phenyl]-(2R,4R)-1 [(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4 (3-exemorpholin-4-yl)phenyl] (2R,4R)-1 [(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorofuran 2 yl)acryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N-[2-fluoro-4 (3-exemorpholin-4-yl)phenyl] (2R,4R) 1 [(E)-3 (5-ehlorofuran-2-yl)acryloyl] 4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-exemorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-ehlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 exemorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (3,4-dichlorophenyl)acryloyl] 4 methoxypyrrolidine 2 carboxamide,

N [2-fluoro 4 (3-exemorpholin-4-yl)phenyl] (2R,4R) 1 [(E) 3 (4-chlorophenyl)acryloyl] 4 ethoxypyrrolidine 2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acrylovl]-4-ethoxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorofuran 2-yl)acryloyl] 4 ethoxypyrrolidine 2 carboxamide;

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5-chlorothiophen 2-yl)acryloyl] 4 ethoxypyrrolidine 2 carboxamide,

N-[4 (3-oxomorpholin-4-yl)phenyl] (2R,4R)-1 [(E)-3-1H-imidazol-4-ylacryloyl]-4ethoxypyrrolidine-2-carboxamide.

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1H-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 1H imidazol 4 ylacryloyl] 4 methoxypyrrolidine 2 carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1H-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-earboxamide-

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl] (2R,4R) 1-[(E)-3-pyridin-3-ylacryloyl] 4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl] (2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 exomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 pyridin 3 ylacryloyl]-4-ethoxypyrrolidine 2 earboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl] (2R,4R) 1-[(E)-3-pyridin-3-ylacryloyl]-4hydroxypyrrolidine-2-carboxamide,

N [4 (3-oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3-pyridin 3-ylacryloyl] 4methoxypyrrolidine 2-carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 pyridin 4 ylacryloyl] 4hydroxypyrrolidine 2 carboxamide,

N-[4 (3-oxomorpholin-4 yl)phenyl] (2R,4R)-1 [(E)-3 pyridin-4 ylacryloyl]-4ethoxypyrrolidine-2 carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1H-imidazol-4-ylacryloyl]-4methoxypyrrolidine-2-carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (4 bromothiophen 2-yl)acryloyl 4 hydroxypyrrolidine 2 carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (4 bromothiophen 2-yl)acrylovl] 4 ethoxypyrrolidine 2 carboxamide.

N-[4-(3-exemorpholin 4-yl)phenyl] (2R,4R) 1-[(E) 3-(5-bromothiophen-2-yl)acryloyl] 4-hydroxypyrrolidine 2-carboxamide.

N-[4-(3-oxomorpholin-4-yl)phenyl] (2R,4R) 1-[(E)-3-(5-bromothiophen-2-yl)acryloyl] 4-ethoxypyrrolidine-2-earboxamide.

N (4 chlorophenyl) (R) 1 [4 (2 oxopiperidin 1 yl)benzoyl]pyrrolidine 2-earboxamide.

N-(4-chlorophenyl) (S) 1-[4-(2-oxopiperidin 1-yl)benzoyl]pyrrolidine 2-earboxamide.

1-N-[(4-chlorophenyl)]-2-N-[[4-(5-oxo-1,4-oxazepan-4-yl)phenyl]]-(R)-pyrrolidine-1-2-dicarboxamide.

1 N [(4 chlorophenyl)] 2 N [[4 (5 oxo 1,4 oxazepan 4 yl)phenyl]] (2R,4R) 4-hydroxypyrrolidine 1,2 dicarboxamide,

1. N [(4 chlorophenyl)] 2. N [[4 ((S) 2 methyl 3 oxomorpholin 4 yl)phenyl]](2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide.

1 N [(4 chlorophenyl)] 2 N [[4 ((S) 2 methyl 3 oxomorpholin 4 yl)phenyl]] (2R) pyrrolidine 1,2 dicarboxamide,

1 N-[(4-chlorophenyl)] 2 N-[[4-((R) 2-methyl 3-oxomorpholin 4-yl)phenyl]]-(2R,4R) 4-hydroxypyrrolidine 1,2-dicarboxamide,

 $\frac{1-N\left[(4\text{-chlorophenyl}\right]\cdot 2\cdot N\cdot \left[\left[4\cdot ((R)\cdot 2\cdot \text{methyl}\cdot 3\cdot \text{oxomorpholin}\cdot 4\cdot \text{yl}\right)\text{phenyl}\right]\right]\cdot (2R) }{\text{pyrrolidine}\cdot 1,2\cdot \text{dicarboxamide}},$

1 N [(4 chlorophenyl)] 2 N [[4 (3 oxomorpholin 4-yl) 2 phenoxyphenyl]] (2R)-pyrrolidine 1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[2-fluoro-4-((R)-2-methyl-3-oxomorpholin-4-yl)-phenyl]] (2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-3-N-{[4-(3-oxomorpholin-4-yl)phenyl]}piperidine-1,3-dicarboxamide.

1-N-[(4-chlorophenyl)]-3-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}piperidine-1.3-dicarboxamide. 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxo-1,4-oxazepan-4-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide.

1-N-[(4-chlorophenyl)]-2-N-{[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

I-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hvdroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hvdroxypyrrolidine-1,2-dicarboxamide.

and pharmaceutically usable <u>prodrug</u> derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 24. (Cancelled):
- 25. (Cancelled):
- (Withdrawn; Currently Amended): A process for the preparation of compounds of the formula I according to claim 1 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, said process comprising
- a) for the preparation of compounds of the formula I in which W is N and G is NH.

a compound of formula II

$$R^{1} \xrightarrow{E} X^{R^{2}} X - Y - T$$

$$\downarrow \\ H$$

in which

R1, R2, E, X, Y and T are as defined in Claim 1, and W is N,

in which

D is as defined in Claim 1,

Of

b) for the preparation of compounds of formula I in which X is $[C(R^4)_{2,1}]_nCONR^2[C(R^4)_{2,1}]_{n-1}$

a compound of formula IV

in which R3, n, Y and T are as defined in Claim 1,

is reacted with a compound of formula V

in which

Lis Cl, Br, I or a free or reactively functionally modified OH group, and R¹, R², R⁴;
D, E, G, W and n are as defined in Claim I.

or

c) for the preparation of compounds of formula I in which W is N,

a compound of formula II

$$R^{1}$$
 \leftarrow E $\xrightarrow{R^{2}}$ $X-Y-T$ H

in which

R1, R2, E, X, Y and T are as defined in Claim 1, and W is N.

is reacted with a compound of formula VI

in which

D and G are as defined in Claim 1, and L is Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.

- 27. (Cancelled):
- 28. (Cancelled):
- (Currently Amended): A medicament composition comprising at least one compound according to claim 1 and one of ore more excipients and/or adjuvants.
- (Previously Presented): A medicament composition comprising at least one compound according to claim 1 and at least one further medicament active ingredient.

- 31. (Withdrawn): A method for the treatment of a patient suffering from thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to said patient an effective amount of a compound according to claim1.
 - 32. (Previously Presented): A kit comprising separate packs of:
 - $\hbox{(a)} \qquad \hbox{an effective amount of a compound according to claim 1,} \\$
 - and
 - (b) an effective amount of a further medicament active ingredient.
- 33. (Withdrawn): A method according to claim 31, further comprising administering to said patient at least one further medicament active ingredient.
 - 34. (Cancelled):
 - 35. (Cancelled):
 - (Cancelled):
 - 37. (Cancelled):
 - (Cancelled):
 - 39. (Cancelled):
- 40. (Withdrawn; Currently Amended): A medicament composition according to Claim 30, wherein said at least one compound is 1-N-[(4-chlorophenyl)]-2-N-[[4-(3oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or a pharmaceutically usable derivative, solvate, salt or stereoisomer stereoisomers thereof,

including mixtures thereof in all ratios, and <u>said</u> at least one further medicament active ingredient is aspirin.

- 41. (Withdrawn; Currently Amended): A method according to Claim 33, wherein 1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-hydroxy-pyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivative, solvate, salt or stereoisomer stereoisomers thereof, including mixtures thereof in all ratios, and aspirin are administered to said patient.
 - 42. (Withdrawn; Currently Amended): A compound according to claim 1, wherein

G is -NH-, and

X is CONH-

Y is Ar-diyl,

Ar is phenyl which is substituted or unsubstituted; and

T is pyrrolidin 1 yl, is monosubstituted or disubstituted by carbonyl oxygen.

- 43. (New): A compound according to claim 1, wherein R¹ is H, =O, COOA, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, methylcarbonyloxy, acetamino, or methylsulfonylamino.
- 44. (New): A compound according to claim 1, wherein R^2 is H, =0, OH, methoxy, or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.
 - 45. (New): A compound according to claim 1, wherein R4 is H.
 - 46. (New): A compound according to claim 1, wherein

- 48. (New): A compound according to claim 1, wherein E is oxazolidine-3,4- or 3,5-diyl.
- 50. (New): A compound according to claim 1, wherein E is 2,5-dihydro-1*H*-pyrrole-1,5-diyl.
- 52. (New): A compound according to claim 1, wherein E is 1,3-oxazinane-3,4-diyl.
 - 53. (New): A compound according to claim 1, wherein

54. (New): A compound according to claim 1, wherein

55. (New): A compound according to claim 1, wherein

$$\left(\begin{array}{c} \mathsf{E} \\ \mathsf{W} \end{array}\right)$$
 is or azetidine-1,2-diyl.

- (New): A compound according to claim 1, wherein D is phenyl which is monosubstituted or disubstituted by Hal.
- (New): A compound according to claim 1, wherein D is pyridyl which is monosubstituted or disubstituted by Hal.
- 58. (New): A compound according to claim 1, wherein D is thienyl which is monosubstituted or disubstituted by Hal.
 - 59. (New): A compound according to claim 1, wherein G is (CH₂)_n.
 - 60. (New): A compound according to claim 1, wherein G is (CH₂)_nNH-.